Photo by nci from unsplash
Key Points Question Is adding a novel macrophage-regulating drug, ON101 cream, to general wound care (GWC) cost-effective compared with GWC alone for treating diabetic foot ulcers (DFUs) from a health… Click to show full abstract
Key Points Question Is adding a novel macrophage-regulating drug, ON101 cream, to general wound care (GWC) cost-effective compared with GWC alone for treating diabetic foot ulcers (DFUs) from a health care sector perspective? Findings In this economic evaluation, the ON101 with GWC strategy vs GWC alone strategy gained more wound healing events, averted more DFU-related complications, and cost $14 922/quality-adjusted life-year gained. Meaning In this study, ON101-enhanced GWC was cost-effective vs GWC alone at a willingness-to-pay threshold of $32 787/quality-adjusted life-year from the Taiwan health care sector perspective and may be considered in future standard wound care.
Journal Title: JAMA Network Open
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!